Review



ha tagged ubiquitin plasmids  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Addgene inc ha tagged ubiquitin plasmids
    Molecular interaction between SDE2 and ATG5. (A) Molecular docking prediction illustrating the interaction between ATG5 and SDE2. (B) Box plot showing significantly elevated ATG5 expression in plasma cells from MM patients compared to healthy controls. Data were obtained from the TCGA database. (C) Kaplan–Meier survival analysis of multiple myeloma (MM) patients stratified by combined expression levels of ATG5 and SDE2. (D) Western blot analysis demonstrating the effect of SDE2 knockdown on ATG5 protein levels in OPM-2 and KMS-11 cells. (E–F) Co-immunoprecipitation (Co-IP) assays in KMS-11 cells using antibodies targeting SDE2 to pull down ATG5 (E) and antibodies targeting ATG5 to pull down SDE2 (F), confirming a direct interaction between the two proteins. (G) HEK 293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2. Immunoprecipitation using anti-Flag antibodies was followed by immunoblotting with anti-Myc (ATG5) and anti-Flag (SDE2) antibodies, validating the interaction between exogenous SDE2 and ATG5. (H) Western blot analysis of ATG5 degradation in SDE2-overexpressing cells treated with the protein synthesis inhibitor cycloheximide (CHX, 10 μg/mL) in the presence of chloroquine (CQ) or MG132. (I) Western blot analysis showing that treatment with MG132 rescues ATG5 degradation in SDE2-overexpressing cells. (J) Schematic representation of full-length and truncation constructs of SDE2. (K) Co-immunoprecipitation of HA-SDE2 variants with Flag-tagged ATG5 in HEK293T cells. Only full-length and 1–300 aa fragment of SDE2 retained the ability to bind ATG5. (L) Cell lysates from SDE2-overexpressing cells (wild-type, Δ1, and Δ2 mutants) were immunoprecipitated with anti-ATG5 antibodies and immunoblotted with anti-Ub and anti-ATG5 antibodies to assess ATG5 ubiquitination levels. (M) HEK 293T cells were co-transfected <t>with</t> <t>HA-tagged</t> <t>ubiquitin</t> (Ub), Myc-tagged ATG5, and Flag-tagged SDE2 (wild-type and Δ1 mutant). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, demonstrating that the SDE2 UBL domain mediates ATG5 ubiquitination. (N) Co-IP analysis of the interaction between ATG5 and the SDE2-Δ1 mutant. HEK293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2-Δ1 plasmids as indicated. Cell lysates were immunoprecipitated with anti-Flag antibody, followed by immunoblotting with anti-Myc and anti-Flag antibodies. Input blots confirmed protein expression levels. (O) M. SDE2-Δ1 fails to promote ATG5 degradation in KMS-11 cells. Cells were transfected with SDE2-Δ1 and treated with or without the proteasome inhibitor MG132 (10 μM, 6 h). (P) HEK 293T cells were co-transfected with Myc-tagged ATG5, Flag-tagged SDE2, and HA-tagged ubiquitin constructs (wild-type, Lys48-only, or Lys63-only). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, confirming that SDE2 facilitates Lys48-linked ubiquitination of ATG5. (Q) Western blot analysis showing ATG5 and SDE2 levels in control and SDE2-overexpressing KMS-11 cells co-expressing wild-type ubiquitin (Ub WT) or ubiquitin with a Lys48-to-Arg mutation (Ub Lys48R) after 72 h of culture. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
    Ha Tagged Ubiquitin Plasmids, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 440 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ha tagged ubiquitin plasmids/product/Addgene inc
    Average 96 stars, based on 440 article reviews
    ha tagged ubiquitin plasmids - by Bioz Stars, 2026-05
    96/100 stars

    Images

    1) Product Images from "Inhibition of SDE2 promotes autophagy-dependent ferroptosis in multiple myeloma"

    Article Title: Inhibition of SDE2 promotes autophagy-dependent ferroptosis in multiple myeloma

    Journal: Redox Biology

    doi: 10.1016/j.redox.2026.104007

    Molecular interaction between SDE2 and ATG5. (A) Molecular docking prediction illustrating the interaction between ATG5 and SDE2. (B) Box plot showing significantly elevated ATG5 expression in plasma cells from MM patients compared to healthy controls. Data were obtained from the TCGA database. (C) Kaplan–Meier survival analysis of multiple myeloma (MM) patients stratified by combined expression levels of ATG5 and SDE2. (D) Western blot analysis demonstrating the effect of SDE2 knockdown on ATG5 protein levels in OPM-2 and KMS-11 cells. (E–F) Co-immunoprecipitation (Co-IP) assays in KMS-11 cells using antibodies targeting SDE2 to pull down ATG5 (E) and antibodies targeting ATG5 to pull down SDE2 (F), confirming a direct interaction between the two proteins. (G) HEK 293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2. Immunoprecipitation using anti-Flag antibodies was followed by immunoblotting with anti-Myc (ATG5) and anti-Flag (SDE2) antibodies, validating the interaction between exogenous SDE2 and ATG5. (H) Western blot analysis of ATG5 degradation in SDE2-overexpressing cells treated with the protein synthesis inhibitor cycloheximide (CHX, 10 μg/mL) in the presence of chloroquine (CQ) or MG132. (I) Western blot analysis showing that treatment with MG132 rescues ATG5 degradation in SDE2-overexpressing cells. (J) Schematic representation of full-length and truncation constructs of SDE2. (K) Co-immunoprecipitation of HA-SDE2 variants with Flag-tagged ATG5 in HEK293T cells. Only full-length and 1–300 aa fragment of SDE2 retained the ability to bind ATG5. (L) Cell lysates from SDE2-overexpressing cells (wild-type, Δ1, and Δ2 mutants) were immunoprecipitated with anti-ATG5 antibodies and immunoblotted with anti-Ub and anti-ATG5 antibodies to assess ATG5 ubiquitination levels. (M) HEK 293T cells were co-transfected with HA-tagged ubiquitin (Ub), Myc-tagged ATG5, and Flag-tagged SDE2 (wild-type and Δ1 mutant). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, demonstrating that the SDE2 UBL domain mediates ATG5 ubiquitination. (N) Co-IP analysis of the interaction between ATG5 and the SDE2-Δ1 mutant. HEK293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2-Δ1 plasmids as indicated. Cell lysates were immunoprecipitated with anti-Flag antibody, followed by immunoblotting with anti-Myc and anti-Flag antibodies. Input blots confirmed protein expression levels. (O) M. SDE2-Δ1 fails to promote ATG5 degradation in KMS-11 cells. Cells were transfected with SDE2-Δ1 and treated with or without the proteasome inhibitor MG132 (10 μM, 6 h). (P) HEK 293T cells were co-transfected with Myc-tagged ATG5, Flag-tagged SDE2, and HA-tagged ubiquitin constructs (wild-type, Lys48-only, or Lys63-only). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, confirming that SDE2 facilitates Lys48-linked ubiquitination of ATG5. (Q) Western blot analysis showing ATG5 and SDE2 levels in control and SDE2-overexpressing KMS-11 cells co-expressing wild-type ubiquitin (Ub WT) or ubiquitin with a Lys48-to-Arg mutation (Ub Lys48R) after 72 h of culture. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
    Figure Legend Snippet: Molecular interaction between SDE2 and ATG5. (A) Molecular docking prediction illustrating the interaction between ATG5 and SDE2. (B) Box plot showing significantly elevated ATG5 expression in plasma cells from MM patients compared to healthy controls. Data were obtained from the TCGA database. (C) Kaplan–Meier survival analysis of multiple myeloma (MM) patients stratified by combined expression levels of ATG5 and SDE2. (D) Western blot analysis demonstrating the effect of SDE2 knockdown on ATG5 protein levels in OPM-2 and KMS-11 cells. (E–F) Co-immunoprecipitation (Co-IP) assays in KMS-11 cells using antibodies targeting SDE2 to pull down ATG5 (E) and antibodies targeting ATG5 to pull down SDE2 (F), confirming a direct interaction between the two proteins. (G) HEK 293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2. Immunoprecipitation using anti-Flag antibodies was followed by immunoblotting with anti-Myc (ATG5) and anti-Flag (SDE2) antibodies, validating the interaction between exogenous SDE2 and ATG5. (H) Western blot analysis of ATG5 degradation in SDE2-overexpressing cells treated with the protein synthesis inhibitor cycloheximide (CHX, 10 μg/mL) in the presence of chloroquine (CQ) or MG132. (I) Western blot analysis showing that treatment with MG132 rescues ATG5 degradation in SDE2-overexpressing cells. (J) Schematic representation of full-length and truncation constructs of SDE2. (K) Co-immunoprecipitation of HA-SDE2 variants with Flag-tagged ATG5 in HEK293T cells. Only full-length and 1–300 aa fragment of SDE2 retained the ability to bind ATG5. (L) Cell lysates from SDE2-overexpressing cells (wild-type, Δ1, and Δ2 mutants) were immunoprecipitated with anti-ATG5 antibodies and immunoblotted with anti-Ub and anti-ATG5 antibodies to assess ATG5 ubiquitination levels. (M) HEK 293T cells were co-transfected with HA-tagged ubiquitin (Ub), Myc-tagged ATG5, and Flag-tagged SDE2 (wild-type and Δ1 mutant). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, demonstrating that the SDE2 UBL domain mediates ATG5 ubiquitination. (N) Co-IP analysis of the interaction between ATG5 and the SDE2-Δ1 mutant. HEK293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2-Δ1 plasmids as indicated. Cell lysates were immunoprecipitated with anti-Flag antibody, followed by immunoblotting with anti-Myc and anti-Flag antibodies. Input blots confirmed protein expression levels. (O) M. SDE2-Δ1 fails to promote ATG5 degradation in KMS-11 cells. Cells were transfected with SDE2-Δ1 and treated with or without the proteasome inhibitor MG132 (10 μM, 6 h). (P) HEK 293T cells were co-transfected with Myc-tagged ATG5, Flag-tagged SDE2, and HA-tagged ubiquitin constructs (wild-type, Lys48-only, or Lys63-only). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, confirming that SDE2 facilitates Lys48-linked ubiquitination of ATG5. (Q) Western blot analysis showing ATG5 and SDE2 levels in control and SDE2-overexpressing KMS-11 cells co-expressing wild-type ubiquitin (Ub WT) or ubiquitin with a Lys48-to-Arg mutation (Ub Lys48R) after 72 h of culture. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.

    Techniques Used: Expressing, Clinical Proteomics, Western Blot, Knockdown, Immunoprecipitation, Co-Immunoprecipitation Assay, Transfection, Construct, Ubiquitin Proteomics, Mutagenesis, Control



    Similar Products

    86
    Hanyin Education Consulting Inc ha ubiquitin plasmid
    Ha Ubiquitin Plasmid, supplied by Hanyin Education Consulting Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ha ubiquitin plasmid/product/Hanyin Education Consulting Inc
    Average 86 stars, based on 1 article reviews
    ha ubiquitin plasmid - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    96
    Addgene inc ha tagged ubiquitin plasmids
    Molecular interaction between SDE2 and ATG5. (A) Molecular docking prediction illustrating the interaction between ATG5 and SDE2. (B) Box plot showing significantly elevated ATG5 expression in plasma cells from MM patients compared to healthy controls. Data were obtained from the TCGA database. (C) Kaplan–Meier survival analysis of multiple myeloma (MM) patients stratified by combined expression levels of ATG5 and SDE2. (D) Western blot analysis demonstrating the effect of SDE2 knockdown on ATG5 protein levels in OPM-2 and KMS-11 cells. (E–F) Co-immunoprecipitation (Co-IP) assays in KMS-11 cells using antibodies targeting SDE2 to pull down ATG5 (E) and antibodies targeting ATG5 to pull down SDE2 (F), confirming a direct interaction between the two proteins. (G) HEK 293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2. Immunoprecipitation using anti-Flag antibodies was followed by immunoblotting with anti-Myc (ATG5) and anti-Flag (SDE2) antibodies, validating the interaction between exogenous SDE2 and ATG5. (H) Western blot analysis of ATG5 degradation in SDE2-overexpressing cells treated with the protein synthesis inhibitor cycloheximide (CHX, 10 μg/mL) in the presence of chloroquine (CQ) or MG132. (I) Western blot analysis showing that treatment with MG132 rescues ATG5 degradation in SDE2-overexpressing cells. (J) Schematic representation of full-length and truncation constructs of SDE2. (K) Co-immunoprecipitation of HA-SDE2 variants with Flag-tagged ATG5 in HEK293T cells. Only full-length and 1–300 aa fragment of SDE2 retained the ability to bind ATG5. (L) Cell lysates from SDE2-overexpressing cells (wild-type, Δ1, and Δ2 mutants) were immunoprecipitated with anti-ATG5 antibodies and immunoblotted with anti-Ub and anti-ATG5 antibodies to assess ATG5 ubiquitination levels. (M) HEK 293T cells were co-transfected <t>with</t> <t>HA-tagged</t> <t>ubiquitin</t> (Ub), Myc-tagged ATG5, and Flag-tagged SDE2 (wild-type and Δ1 mutant). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, demonstrating that the SDE2 UBL domain mediates ATG5 ubiquitination. (N) Co-IP analysis of the interaction between ATG5 and the SDE2-Δ1 mutant. HEK293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2-Δ1 plasmids as indicated. Cell lysates were immunoprecipitated with anti-Flag antibody, followed by immunoblotting with anti-Myc and anti-Flag antibodies. Input blots confirmed protein expression levels. (O) M. SDE2-Δ1 fails to promote ATG5 degradation in KMS-11 cells. Cells were transfected with SDE2-Δ1 and treated with or without the proteasome inhibitor MG132 (10 μM, 6 h). (P) HEK 293T cells were co-transfected with Myc-tagged ATG5, Flag-tagged SDE2, and HA-tagged ubiquitin constructs (wild-type, Lys48-only, or Lys63-only). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, confirming that SDE2 facilitates Lys48-linked ubiquitination of ATG5. (Q) Western blot analysis showing ATG5 and SDE2 levels in control and SDE2-overexpressing KMS-11 cells co-expressing wild-type ubiquitin (Ub WT) or ubiquitin with a Lys48-to-Arg mutation (Ub Lys48R) after 72 h of culture. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
    Ha Tagged Ubiquitin Plasmids, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ha tagged ubiquitin plasmids/product/Addgene inc
    Average 96 stars, based on 1 article reviews
    ha tagged ubiquitin plasmids - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    96
    Addgene inc plasmid
    Molecular interaction between SDE2 and ATG5. (A) Molecular docking prediction illustrating the interaction between ATG5 and SDE2. (B) Box plot showing significantly elevated ATG5 expression in plasma cells from MM patients compared to healthy controls. Data were obtained from the TCGA database. (C) Kaplan–Meier survival analysis of multiple myeloma (MM) patients stratified by combined expression levels of ATG5 and SDE2. (D) Western blot analysis demonstrating the effect of SDE2 knockdown on ATG5 protein levels in OPM-2 and KMS-11 cells. (E–F) Co-immunoprecipitation (Co-IP) assays in KMS-11 cells using antibodies targeting SDE2 to pull down ATG5 (E) and antibodies targeting ATG5 to pull down SDE2 (F), confirming a direct interaction between the two proteins. (G) HEK 293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2. Immunoprecipitation using anti-Flag antibodies was followed by immunoblotting with anti-Myc (ATG5) and anti-Flag (SDE2) antibodies, validating the interaction between exogenous SDE2 and ATG5. (H) Western blot analysis of ATG5 degradation in SDE2-overexpressing cells treated with the protein synthesis inhibitor cycloheximide (CHX, 10 μg/mL) in the presence of chloroquine (CQ) or MG132. (I) Western blot analysis showing that treatment with MG132 rescues ATG5 degradation in SDE2-overexpressing cells. (J) Schematic representation of full-length and truncation constructs of SDE2. (K) Co-immunoprecipitation of HA-SDE2 variants with Flag-tagged ATG5 in HEK293T cells. Only full-length and 1–300 aa fragment of SDE2 retained the ability to bind ATG5. (L) Cell lysates from SDE2-overexpressing cells (wild-type, Δ1, and Δ2 mutants) were immunoprecipitated with anti-ATG5 antibodies and immunoblotted with anti-Ub and anti-ATG5 antibodies to assess ATG5 ubiquitination levels. (M) HEK 293T cells were co-transfected <t>with</t> <t>HA-tagged</t> <t>ubiquitin</t> (Ub), Myc-tagged ATG5, and Flag-tagged SDE2 (wild-type and Δ1 mutant). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, demonstrating that the SDE2 UBL domain mediates ATG5 ubiquitination. (N) Co-IP analysis of the interaction between ATG5 and the SDE2-Δ1 mutant. HEK293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2-Δ1 plasmids as indicated. Cell lysates were immunoprecipitated with anti-Flag antibody, followed by immunoblotting with anti-Myc and anti-Flag antibodies. Input blots confirmed protein expression levels. (O) M. SDE2-Δ1 fails to promote ATG5 degradation in KMS-11 cells. Cells were transfected with SDE2-Δ1 and treated with or without the proteasome inhibitor MG132 (10 μM, 6 h). (P) HEK 293T cells were co-transfected with Myc-tagged ATG5, Flag-tagged SDE2, and HA-tagged ubiquitin constructs (wild-type, Lys48-only, or Lys63-only). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, confirming that SDE2 facilitates Lys48-linked ubiquitination of ATG5. (Q) Western blot analysis showing ATG5 and SDE2 levels in control and SDE2-overexpressing KMS-11 cells co-expressing wild-type ubiquitin (Ub WT) or ubiquitin with a Lys48-to-Arg mutation (Ub Lys48R) after 72 h of culture. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
    Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasmid/product/Addgene inc
    Average 96 stars, based on 1 article reviews
    plasmid - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    96
    Addgene inc ted dawson
    Molecular interaction between SDE2 and ATG5. (A) Molecular docking prediction illustrating the interaction between ATG5 and SDE2. (B) Box plot showing significantly elevated ATG5 expression in plasma cells from MM patients compared to healthy controls. Data were obtained from the TCGA database. (C) Kaplan–Meier survival analysis of multiple myeloma (MM) patients stratified by combined expression levels of ATG5 and SDE2. (D) Western blot analysis demonstrating the effect of SDE2 knockdown on ATG5 protein levels in OPM-2 and KMS-11 cells. (E–F) Co-immunoprecipitation (Co-IP) assays in KMS-11 cells using antibodies targeting SDE2 to pull down ATG5 (E) and antibodies targeting ATG5 to pull down SDE2 (F), confirming a direct interaction between the two proteins. (G) HEK 293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2. Immunoprecipitation using anti-Flag antibodies was followed by immunoblotting with anti-Myc (ATG5) and anti-Flag (SDE2) antibodies, validating the interaction between exogenous SDE2 and ATG5. (H) Western blot analysis of ATG5 degradation in SDE2-overexpressing cells treated with the protein synthesis inhibitor cycloheximide (CHX, 10 μg/mL) in the presence of chloroquine (CQ) or MG132. (I) Western blot analysis showing that treatment with MG132 rescues ATG5 degradation in SDE2-overexpressing cells. (J) Schematic representation of full-length and truncation constructs of SDE2. (K) Co-immunoprecipitation of HA-SDE2 variants with Flag-tagged ATG5 in HEK293T cells. Only full-length and 1–300 aa fragment of SDE2 retained the ability to bind ATG5. (L) Cell lysates from SDE2-overexpressing cells (wild-type, Δ1, and Δ2 mutants) were immunoprecipitated with anti-ATG5 antibodies and immunoblotted with anti-Ub and anti-ATG5 antibodies to assess ATG5 ubiquitination levels. (M) HEK 293T cells were co-transfected <t>with</t> <t>HA-tagged</t> <t>ubiquitin</t> (Ub), Myc-tagged ATG5, and Flag-tagged SDE2 (wild-type and Δ1 mutant). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, demonstrating that the SDE2 UBL domain mediates ATG5 ubiquitination. (N) Co-IP analysis of the interaction between ATG5 and the SDE2-Δ1 mutant. HEK293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2-Δ1 plasmids as indicated. Cell lysates were immunoprecipitated with anti-Flag antibody, followed by immunoblotting with anti-Myc and anti-Flag antibodies. Input blots confirmed protein expression levels. (O) M. SDE2-Δ1 fails to promote ATG5 degradation in KMS-11 cells. Cells were transfected with SDE2-Δ1 and treated with or without the proteasome inhibitor MG132 (10 μM, 6 h). (P) HEK 293T cells were co-transfected with Myc-tagged ATG5, Flag-tagged SDE2, and HA-tagged ubiquitin constructs (wild-type, Lys48-only, or Lys63-only). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, confirming that SDE2 facilitates Lys48-linked ubiquitination of ATG5. (Q) Western blot analysis showing ATG5 and SDE2 levels in control and SDE2-overexpressing KMS-11 cells co-expressing wild-type ubiquitin (Ub WT) or ubiquitin with a Lys48-to-Arg mutation (Ub Lys48R) after 72 h of culture. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
    Ted Dawson, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ted dawson/product/Addgene inc
    Average 96 stars, based on 1 article reviews
    ted dawson - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    93
    Addgene inc prk5 ha ubiquitin 27 6a
    Molecular interaction between SDE2 and ATG5. (A) Molecular docking prediction illustrating the interaction between ATG5 and SDE2. (B) Box plot showing significantly elevated ATG5 expression in plasma cells from MM patients compared to healthy controls. Data were obtained from the TCGA database. (C) Kaplan–Meier survival analysis of multiple myeloma (MM) patients stratified by combined expression levels of ATG5 and SDE2. (D) Western blot analysis demonstrating the effect of SDE2 knockdown on ATG5 protein levels in OPM-2 and KMS-11 cells. (E–F) Co-immunoprecipitation (Co-IP) assays in KMS-11 cells using antibodies targeting SDE2 to pull down ATG5 (E) and antibodies targeting ATG5 to pull down SDE2 (F), confirming a direct interaction between the two proteins. (G) HEK 293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2. Immunoprecipitation using anti-Flag antibodies was followed by immunoblotting with anti-Myc (ATG5) and anti-Flag (SDE2) antibodies, validating the interaction between exogenous SDE2 and ATG5. (H) Western blot analysis of ATG5 degradation in SDE2-overexpressing cells treated with the protein synthesis inhibitor cycloheximide (CHX, 10 μg/mL) in the presence of chloroquine (CQ) or MG132. (I) Western blot analysis showing that treatment with MG132 rescues ATG5 degradation in SDE2-overexpressing cells. (J) Schematic representation of full-length and truncation constructs of SDE2. (K) Co-immunoprecipitation of HA-SDE2 variants with Flag-tagged ATG5 in HEK293T cells. Only full-length and 1–300 aa fragment of SDE2 retained the ability to bind ATG5. (L) Cell lysates from SDE2-overexpressing cells (wild-type, Δ1, and Δ2 mutants) were immunoprecipitated with anti-ATG5 antibodies and immunoblotted with anti-Ub and anti-ATG5 antibodies to assess ATG5 ubiquitination levels. (M) HEK 293T cells were co-transfected <t>with</t> <t>HA-tagged</t> <t>ubiquitin</t> (Ub), Myc-tagged ATG5, and Flag-tagged SDE2 (wild-type and Δ1 mutant). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, demonstrating that the SDE2 UBL domain mediates ATG5 ubiquitination. (N) Co-IP analysis of the interaction between ATG5 and the SDE2-Δ1 mutant. HEK293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2-Δ1 plasmids as indicated. Cell lysates were immunoprecipitated with anti-Flag antibody, followed by immunoblotting with anti-Myc and anti-Flag antibodies. Input blots confirmed protein expression levels. (O) M. SDE2-Δ1 fails to promote ATG5 degradation in KMS-11 cells. Cells were transfected with SDE2-Δ1 and treated with or without the proteasome inhibitor MG132 (10 μM, 6 h). (P) HEK 293T cells were co-transfected with Myc-tagged ATG5, Flag-tagged SDE2, and HA-tagged ubiquitin constructs (wild-type, Lys48-only, or Lys63-only). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, confirming that SDE2 facilitates Lys48-linked ubiquitination of ATG5. (Q) Western blot analysis showing ATG5 and SDE2 levels in control and SDE2-overexpressing KMS-11 cells co-expressing wild-type ubiquitin (Ub WT) or ubiquitin with a Lys48-to-Arg mutation (Ub Lys48R) after 72 h of culture. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
    Prk5 Ha Ubiquitin 27 6a, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/prk5 ha ubiquitin 27 6a/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    prk5 ha ubiquitin 27 6a - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    96
    Addgene inc paper n a prk5 ha ubiquitin wt addgene 17608 prk5 ha ubiquitin k48 addgene 17605 pcdna4 pink1 wt 3xflag
    Molecular interaction between SDE2 and ATG5. (A) Molecular docking prediction illustrating the interaction between ATG5 and SDE2. (B) Box plot showing significantly elevated ATG5 expression in plasma cells from MM patients compared to healthy controls. Data were obtained from the TCGA database. (C) Kaplan–Meier survival analysis of multiple myeloma (MM) patients stratified by combined expression levels of ATG5 and SDE2. (D) Western blot analysis demonstrating the effect of SDE2 knockdown on ATG5 protein levels in OPM-2 and KMS-11 cells. (E–F) Co-immunoprecipitation (Co-IP) assays in KMS-11 cells using antibodies targeting SDE2 to pull down ATG5 (E) and antibodies targeting ATG5 to pull down SDE2 (F), confirming a direct interaction between the two proteins. (G) HEK 293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2. Immunoprecipitation using anti-Flag antibodies was followed by immunoblotting with anti-Myc (ATG5) and anti-Flag (SDE2) antibodies, validating the interaction between exogenous SDE2 and ATG5. (H) Western blot analysis of ATG5 degradation in SDE2-overexpressing cells treated with the protein synthesis inhibitor cycloheximide (CHX, 10 μg/mL) in the presence of chloroquine (CQ) or MG132. (I) Western blot analysis showing that treatment with MG132 rescues ATG5 degradation in SDE2-overexpressing cells. (J) Schematic representation of full-length and truncation constructs of SDE2. (K) Co-immunoprecipitation of HA-SDE2 variants with Flag-tagged ATG5 in HEK293T cells. Only full-length and 1–300 aa fragment of SDE2 retained the ability to bind ATG5. (L) Cell lysates from SDE2-overexpressing cells (wild-type, Δ1, and Δ2 mutants) were immunoprecipitated with anti-ATG5 antibodies and immunoblotted with anti-Ub and anti-ATG5 antibodies to assess ATG5 ubiquitination levels. (M) HEK 293T cells were co-transfected <t>with</t> <t>HA-tagged</t> <t>ubiquitin</t> (Ub), Myc-tagged ATG5, and Flag-tagged SDE2 (wild-type and Δ1 mutant). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, demonstrating that the SDE2 UBL domain mediates ATG5 ubiquitination. (N) Co-IP analysis of the interaction between ATG5 and the SDE2-Δ1 mutant. HEK293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2-Δ1 plasmids as indicated. Cell lysates were immunoprecipitated with anti-Flag antibody, followed by immunoblotting with anti-Myc and anti-Flag antibodies. Input blots confirmed protein expression levels. (O) M. SDE2-Δ1 fails to promote ATG5 degradation in KMS-11 cells. Cells were transfected with SDE2-Δ1 and treated with or without the proteasome inhibitor MG132 (10 μM, 6 h). (P) HEK 293T cells were co-transfected with Myc-tagged ATG5, Flag-tagged SDE2, and HA-tagged ubiquitin constructs (wild-type, Lys48-only, or Lys63-only). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, confirming that SDE2 facilitates Lys48-linked ubiquitination of ATG5. (Q) Western blot analysis showing ATG5 and SDE2 levels in control and SDE2-overexpressing KMS-11 cells co-expressing wild-type ubiquitin (Ub WT) or ubiquitin with a Lys48-to-Arg mutation (Ub Lys48R) after 72 h of culture. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
    Paper N A Prk5 Ha Ubiquitin Wt Addgene 17608 Prk5 Ha Ubiquitin K48 Addgene 17605 Pcdna4 Pink1 Wt 3xflag, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/paper n a prk5 ha ubiquitin wt addgene 17608 prk5 ha ubiquitin k48 addgene 17605 pcdna4 pink1 wt 3xflag/product/Addgene inc
    Average 96 stars, based on 1 article reviews
    paper n a prk5 ha ubiquitin wt addgene 17608 prk5 ha ubiquitin k48 addgene 17605 pcdna4 pink1 wt 3xflag - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    92
    Addgene inc prk5 ha ubiquitin k0 7a
    Molecular interaction between SDE2 and ATG5. (A) Molecular docking prediction illustrating the interaction between ATG5 and SDE2. (B) Box plot showing significantly elevated ATG5 expression in plasma cells from MM patients compared to healthy controls. Data were obtained from the TCGA database. (C) Kaplan–Meier survival analysis of multiple myeloma (MM) patients stratified by combined expression levels of ATG5 and SDE2. (D) Western blot analysis demonstrating the effect of SDE2 knockdown on ATG5 protein levels in OPM-2 and KMS-11 cells. (E–F) Co-immunoprecipitation (Co-IP) assays in KMS-11 cells using antibodies targeting SDE2 to pull down ATG5 (E) and antibodies targeting ATG5 to pull down SDE2 (F), confirming a direct interaction between the two proteins. (G) HEK 293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2. Immunoprecipitation using anti-Flag antibodies was followed by immunoblotting with anti-Myc (ATG5) and anti-Flag (SDE2) antibodies, validating the interaction between exogenous SDE2 and ATG5. (H) Western blot analysis of ATG5 degradation in SDE2-overexpressing cells treated with the protein synthesis inhibitor cycloheximide (CHX, 10 μg/mL) in the presence of chloroquine (CQ) or MG132. (I) Western blot analysis showing that treatment with MG132 rescues ATG5 degradation in SDE2-overexpressing cells. (J) Schematic representation of full-length and truncation constructs of SDE2. (K) Co-immunoprecipitation of HA-SDE2 variants with Flag-tagged ATG5 in HEK293T cells. Only full-length and 1–300 aa fragment of SDE2 retained the ability to bind ATG5. (L) Cell lysates from SDE2-overexpressing cells (wild-type, Δ1, and Δ2 mutants) were immunoprecipitated with anti-ATG5 antibodies and immunoblotted with anti-Ub and anti-ATG5 antibodies to assess ATG5 ubiquitination levels. (M) HEK 293T cells were co-transfected <t>with</t> <t>HA-tagged</t> <t>ubiquitin</t> (Ub), Myc-tagged ATG5, and Flag-tagged SDE2 (wild-type and Δ1 mutant). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, demonstrating that the SDE2 UBL domain mediates ATG5 ubiquitination. (N) Co-IP analysis of the interaction between ATG5 and the SDE2-Δ1 mutant. HEK293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2-Δ1 plasmids as indicated. Cell lysates were immunoprecipitated with anti-Flag antibody, followed by immunoblotting with anti-Myc and anti-Flag antibodies. Input blots confirmed protein expression levels. (O) M. SDE2-Δ1 fails to promote ATG5 degradation in KMS-11 cells. Cells were transfected with SDE2-Δ1 and treated with or without the proteasome inhibitor MG132 (10 μM, 6 h). (P) HEK 293T cells were co-transfected with Myc-tagged ATG5, Flag-tagged SDE2, and HA-tagged ubiquitin constructs (wild-type, Lys48-only, or Lys63-only). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, confirming that SDE2 facilitates Lys48-linked ubiquitination of ATG5. (Q) Western blot analysis showing ATG5 and SDE2 levels in control and SDE2-overexpressing KMS-11 cells co-expressing wild-type ubiquitin (Ub WT) or ubiquitin with a Lys48-to-Arg mutation (Ub Lys48R) after 72 h of culture. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
    Prk5 Ha Ubiquitin K0 7a, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/prk5 ha ubiquitin k0 7a/product/Addgene inc
    Average 92 stars, based on 1 article reviews
    prk5 ha ubiquitin k0 7a - by Bioz Stars, 2026-05
    92/100 stars
      Buy from Supplier

    94
    Addgene inc ha ub k48 plasmid
    Molecular interaction between SDE2 and ATG5. (A) Molecular docking prediction illustrating the interaction between ATG5 and SDE2. (B) Box plot showing significantly elevated ATG5 expression in plasma cells from MM patients compared to healthy controls. Data were obtained from the TCGA database. (C) Kaplan–Meier survival analysis of multiple myeloma (MM) patients stratified by combined expression levels of ATG5 and SDE2. (D) Western blot analysis demonstrating the effect of SDE2 knockdown on ATG5 protein levels in OPM-2 and KMS-11 cells. (E–F) Co-immunoprecipitation (Co-IP) assays in KMS-11 cells using antibodies targeting SDE2 to pull down ATG5 (E) and antibodies targeting ATG5 to pull down SDE2 (F), confirming a direct interaction between the two proteins. (G) HEK 293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2. Immunoprecipitation using anti-Flag antibodies was followed by immunoblotting with anti-Myc (ATG5) and anti-Flag (SDE2) antibodies, validating the interaction between exogenous SDE2 and ATG5. (H) Western blot analysis of ATG5 degradation in SDE2-overexpressing cells treated with the protein synthesis inhibitor cycloheximide (CHX, 10 μg/mL) in the presence of chloroquine (CQ) or MG132. (I) Western blot analysis showing that treatment with MG132 rescues ATG5 degradation in SDE2-overexpressing cells. (J) Schematic representation of full-length and truncation constructs of SDE2. (K) Co-immunoprecipitation of HA-SDE2 variants with Flag-tagged ATG5 in HEK293T cells. Only full-length and 1–300 aa fragment of SDE2 retained the ability to bind ATG5. (L) Cell lysates from SDE2-overexpressing cells (wild-type, Δ1, and Δ2 mutants) were immunoprecipitated with anti-ATG5 antibodies and immunoblotted with anti-Ub and anti-ATG5 antibodies to assess ATG5 ubiquitination levels. (M) HEK 293T cells were co-transfected <t>with</t> <t>HA-tagged</t> <t>ubiquitin</t> (Ub), Myc-tagged ATG5, and Flag-tagged SDE2 (wild-type and Δ1 mutant). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, demonstrating that the SDE2 UBL domain mediates ATG5 ubiquitination. (N) Co-IP analysis of the interaction between ATG5 and the SDE2-Δ1 mutant. HEK293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2-Δ1 plasmids as indicated. Cell lysates were immunoprecipitated with anti-Flag antibody, followed by immunoblotting with anti-Myc and anti-Flag antibodies. Input blots confirmed protein expression levels. (O) M. SDE2-Δ1 fails to promote ATG5 degradation in KMS-11 cells. Cells were transfected with SDE2-Δ1 and treated with or without the proteasome inhibitor MG132 (10 μM, 6 h). (P) HEK 293T cells were co-transfected with Myc-tagged ATG5, Flag-tagged SDE2, and HA-tagged ubiquitin constructs (wild-type, Lys48-only, or Lys63-only). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, confirming that SDE2 facilitates Lys48-linked ubiquitination of ATG5. (Q) Western blot analysis showing ATG5 and SDE2 levels in control and SDE2-overexpressing KMS-11 cells co-expressing wild-type ubiquitin (Ub WT) or ubiquitin with a Lys48-to-Arg mutation (Ub Lys48R) after 72 h of culture. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
    Ha Ub K48 Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ha ub k48 plasmid/product/Addgene inc
    Average 94 stars, based on 1 article reviews
    ha ub k48 plasmid - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    95
    R&D Systems ha ub
    Molecular interaction between SDE2 and ATG5. (A) Molecular docking prediction illustrating the interaction between ATG5 and SDE2. (B) Box plot showing significantly elevated ATG5 expression in plasma cells from MM patients compared to healthy controls. Data were obtained from the TCGA database. (C) Kaplan–Meier survival analysis of multiple myeloma (MM) patients stratified by combined expression levels of ATG5 and SDE2. (D) Western blot analysis demonstrating the effect of SDE2 knockdown on ATG5 protein levels in OPM-2 and KMS-11 cells. (E–F) Co-immunoprecipitation (Co-IP) assays in KMS-11 cells using antibodies targeting SDE2 to pull down ATG5 (E) and antibodies targeting ATG5 to pull down SDE2 (F), confirming a direct interaction between the two proteins. (G) HEK 293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2. Immunoprecipitation using anti-Flag antibodies was followed by immunoblotting with anti-Myc (ATG5) and anti-Flag (SDE2) antibodies, validating the interaction between exogenous SDE2 and ATG5. (H) Western blot analysis of ATG5 degradation in SDE2-overexpressing cells treated with the protein synthesis inhibitor cycloheximide (CHX, 10 μg/mL) in the presence of chloroquine (CQ) or MG132. (I) Western blot analysis showing that treatment with MG132 rescues ATG5 degradation in SDE2-overexpressing cells. (J) Schematic representation of full-length and truncation constructs of SDE2. (K) Co-immunoprecipitation of HA-SDE2 variants with Flag-tagged ATG5 in HEK293T cells. Only full-length and 1–300 aa fragment of SDE2 retained the ability to bind ATG5. (L) Cell lysates from SDE2-overexpressing cells (wild-type, Δ1, and Δ2 mutants) were immunoprecipitated with anti-ATG5 antibodies and immunoblotted with anti-Ub and anti-ATG5 antibodies to assess ATG5 ubiquitination levels. (M) HEK 293T cells were co-transfected <t>with</t> <t>HA-tagged</t> <t>ubiquitin</t> (Ub), Myc-tagged ATG5, and Flag-tagged SDE2 (wild-type and Δ1 mutant). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, demonstrating that the SDE2 UBL domain mediates ATG5 ubiquitination. (N) Co-IP analysis of the interaction between ATG5 and the SDE2-Δ1 mutant. HEK293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2-Δ1 plasmids as indicated. Cell lysates were immunoprecipitated with anti-Flag antibody, followed by immunoblotting with anti-Myc and anti-Flag antibodies. Input blots confirmed protein expression levels. (O) M. SDE2-Δ1 fails to promote ATG5 degradation in KMS-11 cells. Cells were transfected with SDE2-Δ1 and treated with or without the proteasome inhibitor MG132 (10 μM, 6 h). (P) HEK 293T cells were co-transfected with Myc-tagged ATG5, Flag-tagged SDE2, and HA-tagged ubiquitin constructs (wild-type, Lys48-only, or Lys63-only). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, confirming that SDE2 facilitates Lys48-linked ubiquitination of ATG5. (Q) Western blot analysis showing ATG5 and SDE2 levels in control and SDE2-overexpressing KMS-11 cells co-expressing wild-type ubiquitin (Ub WT) or ubiquitin with a Lys48-to-Arg mutation (Ub Lys48R) after 72 h of culture. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
    Ha Ub, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ha ub/product/R&D Systems
    Average 95 stars, based on 1 article reviews
    ha ub - by Bioz Stars, 2026-05
    95/100 stars
      Buy from Supplier

    Image Search Results


    Molecular interaction between SDE2 and ATG5. (A) Molecular docking prediction illustrating the interaction between ATG5 and SDE2. (B) Box plot showing significantly elevated ATG5 expression in plasma cells from MM patients compared to healthy controls. Data were obtained from the TCGA database. (C) Kaplan–Meier survival analysis of multiple myeloma (MM) patients stratified by combined expression levels of ATG5 and SDE2. (D) Western blot analysis demonstrating the effect of SDE2 knockdown on ATG5 protein levels in OPM-2 and KMS-11 cells. (E–F) Co-immunoprecipitation (Co-IP) assays in KMS-11 cells using antibodies targeting SDE2 to pull down ATG5 (E) and antibodies targeting ATG5 to pull down SDE2 (F), confirming a direct interaction between the two proteins. (G) HEK 293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2. Immunoprecipitation using anti-Flag antibodies was followed by immunoblotting with anti-Myc (ATG5) and anti-Flag (SDE2) antibodies, validating the interaction between exogenous SDE2 and ATG5. (H) Western blot analysis of ATG5 degradation in SDE2-overexpressing cells treated with the protein synthesis inhibitor cycloheximide (CHX, 10 μg/mL) in the presence of chloroquine (CQ) or MG132. (I) Western blot analysis showing that treatment with MG132 rescues ATG5 degradation in SDE2-overexpressing cells. (J) Schematic representation of full-length and truncation constructs of SDE2. (K) Co-immunoprecipitation of HA-SDE2 variants with Flag-tagged ATG5 in HEK293T cells. Only full-length and 1–300 aa fragment of SDE2 retained the ability to bind ATG5. (L) Cell lysates from SDE2-overexpressing cells (wild-type, Δ1, and Δ2 mutants) were immunoprecipitated with anti-ATG5 antibodies and immunoblotted with anti-Ub and anti-ATG5 antibodies to assess ATG5 ubiquitination levels. (M) HEK 293T cells were co-transfected with HA-tagged ubiquitin (Ub), Myc-tagged ATG5, and Flag-tagged SDE2 (wild-type and Δ1 mutant). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, demonstrating that the SDE2 UBL domain mediates ATG5 ubiquitination. (N) Co-IP analysis of the interaction between ATG5 and the SDE2-Δ1 mutant. HEK293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2-Δ1 plasmids as indicated. Cell lysates were immunoprecipitated with anti-Flag antibody, followed by immunoblotting with anti-Myc and anti-Flag antibodies. Input blots confirmed protein expression levels. (O) M. SDE2-Δ1 fails to promote ATG5 degradation in KMS-11 cells. Cells were transfected with SDE2-Δ1 and treated with or without the proteasome inhibitor MG132 (10 μM, 6 h). (P) HEK 293T cells were co-transfected with Myc-tagged ATG5, Flag-tagged SDE2, and HA-tagged ubiquitin constructs (wild-type, Lys48-only, or Lys63-only). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, confirming that SDE2 facilitates Lys48-linked ubiquitination of ATG5. (Q) Western blot analysis showing ATG5 and SDE2 levels in control and SDE2-overexpressing KMS-11 cells co-expressing wild-type ubiquitin (Ub WT) or ubiquitin with a Lys48-to-Arg mutation (Ub Lys48R) after 72 h of culture. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.

    Journal: Redox Biology

    Article Title: Inhibition of SDE2 promotes autophagy-dependent ferroptosis in multiple myeloma

    doi: 10.1016/j.redox.2026.104007

    Figure Lengend Snippet: Molecular interaction between SDE2 and ATG5. (A) Molecular docking prediction illustrating the interaction between ATG5 and SDE2. (B) Box plot showing significantly elevated ATG5 expression in plasma cells from MM patients compared to healthy controls. Data were obtained from the TCGA database. (C) Kaplan–Meier survival analysis of multiple myeloma (MM) patients stratified by combined expression levels of ATG5 and SDE2. (D) Western blot analysis demonstrating the effect of SDE2 knockdown on ATG5 protein levels in OPM-2 and KMS-11 cells. (E–F) Co-immunoprecipitation (Co-IP) assays in KMS-11 cells using antibodies targeting SDE2 to pull down ATG5 (E) and antibodies targeting ATG5 to pull down SDE2 (F), confirming a direct interaction between the two proteins. (G) HEK 293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2. Immunoprecipitation using anti-Flag antibodies was followed by immunoblotting with anti-Myc (ATG5) and anti-Flag (SDE2) antibodies, validating the interaction between exogenous SDE2 and ATG5. (H) Western blot analysis of ATG5 degradation in SDE2-overexpressing cells treated with the protein synthesis inhibitor cycloheximide (CHX, 10 μg/mL) in the presence of chloroquine (CQ) or MG132. (I) Western blot analysis showing that treatment with MG132 rescues ATG5 degradation in SDE2-overexpressing cells. (J) Schematic representation of full-length and truncation constructs of SDE2. (K) Co-immunoprecipitation of HA-SDE2 variants with Flag-tagged ATG5 in HEK293T cells. Only full-length and 1–300 aa fragment of SDE2 retained the ability to bind ATG5. (L) Cell lysates from SDE2-overexpressing cells (wild-type, Δ1, and Δ2 mutants) were immunoprecipitated with anti-ATG5 antibodies and immunoblotted with anti-Ub and anti-ATG5 antibodies to assess ATG5 ubiquitination levels. (M) HEK 293T cells were co-transfected with HA-tagged ubiquitin (Ub), Myc-tagged ATG5, and Flag-tagged SDE2 (wild-type and Δ1 mutant). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, demonstrating that the SDE2 UBL domain mediates ATG5 ubiquitination. (N) Co-IP analysis of the interaction between ATG5 and the SDE2-Δ1 mutant. HEK293T cells were co-transfected with Myc-tagged ATG5 and Flag-tagged SDE2-Δ1 plasmids as indicated. Cell lysates were immunoprecipitated with anti-Flag antibody, followed by immunoblotting with anti-Myc and anti-Flag antibodies. Input blots confirmed protein expression levels. (O) M. SDE2-Δ1 fails to promote ATG5 degradation in KMS-11 cells. Cells were transfected with SDE2-Δ1 and treated with or without the proteasome inhibitor MG132 (10 μM, 6 h). (P) HEK 293T cells were co-transfected with Myc-tagged ATG5, Flag-tagged SDE2, and HA-tagged ubiquitin constructs (wild-type, Lys48-only, or Lys63-only). Immunoprecipitation using anti-Myc antibodies was followed by immunoblotting with anti-HA and anti-Myc antibodies, confirming that SDE2 facilitates Lys48-linked ubiquitination of ATG5. (Q) Western blot analysis showing ATG5 and SDE2 levels in control and SDE2-overexpressing KMS-11 cells co-expressing wild-type ubiquitin (Ub WT) or ubiquitin with a Lys48-to-Arg mutation (Ub Lys48R) after 72 h of culture. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.

    Article Snippet: Ubiquitination Assay Plasmids: HA-tagged ubiquitin plasmids (wild-type: #17608; K48-linked: #17605; K63-linked: #17606) were obtained from Addgene.

    Techniques: Expressing, Clinical Proteomics, Western Blot, Knockdown, Immunoprecipitation, Co-Immunoprecipitation Assay, Transfection, Construct, Ubiquitin Proteomics, Mutagenesis, Control